Sara Miller
Concepts (723)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wasps | 7 | 2023 | 23 | 2.780 |
Why?
| | Selection, Genetic | 6 | 2025 | 269 | 2.550 |
Why?
| | Alcohol Drinking | 8 | 2026 | 847 | 2.410 |
Why?
| | Cognition | 8 | 2026 | 1286 | 1.870 |
Why?
| | Biological Evolution | 6 | 2025 | 471 | 1.830 |
Why?
| | Smegmamorpha | 4 | 2019 | 6 | 1.780 |
Why?
| | Behavior, Animal | 4 | 2021 | 530 | 1.200 |
Why?
| | Coronavirus | 2 | 2020 | 47 | 1.190 |
Why?
| | Hemostatics | 2 | 2026 | 65 | 1.120 |
Why?
| | Coronavirus Infections | 5 | 2020 | 379 | 1.120 |
Why?
| | Microscopy, Electron | 11 | 2022 | 384 | 1.110 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 387 | 1.000 |
Why?
| | Substance Abuse, Intravenous | 2 | 2025 | 131 | 1.000 |
Why?
| | Postpartum Hemorrhage | 1 | 2026 | 28 | 0.930 |
Why?
| | Memory Disorders | 3 | 2023 | 197 | 0.920 |
Why?
| | Surgery, Computer-Assisted | 3 | 2018 | 86 | 0.880 |
Why?
| | Pandemics | 7 | 2024 | 1700 | 0.870 |
Why?
| | Microscopy, Electron, Transmission | 6 | 2021 | 150 | 0.860 |
Why?
| | Genetic Fitness | 1 | 2025 | 60 | 0.850 |
Why?
| | Substance-Related Disorders | 3 | 2023 | 1098 | 0.830 |
Why?
| | Academic Performance | 1 | 2024 | 16 | 0.810 |
Why?
| | Optical Imaging | 3 | 2019 | 63 | 0.800 |
Why?
| | Diabetes, Gestational | 2 | 2025 | 307 | 0.790 |
Why?
| | Individuality | 1 | 2025 | 152 | 0.780 |
Why?
| | Amnesia, Anterograde | 1 | 2023 | 7 | 0.760 |
Why?
| | Humans | 97 | 2026 | 145625 | 0.720 |
Why?
| | Placenta Accreta | 1 | 2022 | 29 | 0.720 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2025 | 272 | 0.720 |
Why?
| | Prescription Drug Misuse | 1 | 2023 | 53 | 0.720 |
Why?
| | Hydrogels | 2 | 2026 | 706 | 0.710 |
Why?
| | Betacoronavirus | 4 | 2020 | 288 | 0.690 |
Why?
| | Archives | 1 | 2021 | 5 | 0.690 |
Why?
| | Entomology | 1 | 2021 | 4 | 0.680 |
Why?
| | Ethology | 1 | 2021 | 3 | 0.670 |
Why?
| | Cellular Structures | 1 | 2021 | 6 | 0.670 |
Why?
| | Data Curation | 1 | 2021 | 21 | 0.670 |
Why?
| | Life History Traits | 1 | 2021 | 15 | 0.660 |
Why?
| | Insecta | 1 | 2021 | 73 | 0.640 |
Why?
| | Genetic Variation | 4 | 2024 | 992 | 0.640 |
Why?
| | Behavior, Addictive | 1 | 2021 | 89 | 0.640 |
Why?
| | Genome | 2 | 2022 | 307 | 0.630 |
Why?
| | Erythrocyte Transfusion | 1 | 2022 | 225 | 0.630 |
Why?
| | Animals | 47 | 2026 | 38030 | 0.630 |
Why?
| | Gestational Age | 1 | 2024 | 989 | 0.630 |
Why?
| | Animal Communication | 1 | 2020 | 18 | 0.620 |
Why?
| | Ecology | 1 | 2021 | 105 | 0.620 |
Why?
| | Infant, Premature | 2 | 2024 | 622 | 0.610 |
Why?
| | Academic Success | 1 | 2019 | 31 | 0.590 |
Why?
| | Food Chain | 2 | 2019 | 36 | 0.580 |
Why?
| | Infant, Low Birth Weight | 1 | 2019 | 154 | 0.570 |
Why?
| | Perciformes | 1 | 2019 | 20 | 0.570 |
Why?
| | Animal Distribution | 1 | 2019 | 27 | 0.560 |
Why?
| | Female | 50 | 2026 | 79080 | 0.540 |
Why?
| | Hip | 1 | 2018 | 57 | 0.530 |
Why?
| | Sex Characteristics | 1 | 2023 | 798 | 0.520 |
Why?
| | Opioid-Related Disorders | 1 | 2025 | 611 | 0.510 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2017 | 54 | 0.500 |
Why?
| | United States | 14 | 2025 | 16041 | 0.500 |
Why?
| | Amputees | 1 | 2018 | 101 | 0.500 |
Why?
| | Optic Nerve Diseases | 1 | 2017 | 49 | 0.490 |
Why?
| | Optic Disk | 1 | 2017 | 53 | 0.490 |
Why?
| | Photography | 1 | 2017 | 120 | 0.490 |
Why?
| | Stress, Psychological | 1 | 2025 | 1169 | 0.470 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1370 | 0.460 |
Why?
| | Child Development | 2 | 2019 | 481 | 0.450 |
Why?
| | Male | 40 | 2026 | 73014 | 0.450 |
Why?
| | Ecosystem | 1 | 2019 | 483 | 0.440 |
Why?
| | Students, Medical | 5 | 2021 | 380 | 0.440 |
Why?
| | Caregivers | 2 | 2021 | 1079 | 0.440 |
Why?
| | Postural Balance | 1 | 2018 | 241 | 0.430 |
Why?
| | Gait | 1 | 2018 | 316 | 0.430 |
Why?
| | Executive Function | 1 | 2019 | 461 | 0.430 |
Why?
| | Artificial Limbs | 1 | 2018 | 215 | 0.420 |
Why?
| | Glioblastoma | 1 | 2018 | 349 | 0.420 |
Why?
| | Phenotype | 5 | 2023 | 3186 | 0.410 |
Why?
| | Molecular Imaging | 3 | 2019 | 58 | 0.410 |
Why?
| | Lower Extremity | 1 | 2018 | 449 | 0.400 |
Why?
| | Glaucoma | 1 | 2017 | 253 | 0.400 |
Why?
| | HIV Infections | 3 | 2025 | 3210 | 0.400 |
Why?
| | Genetics, Population | 3 | 2020 | 225 | 0.390 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2021 | 889 | 0.380 |
Why?
| | Longitudinal Studies | 4 | 2025 | 3005 | 0.340 |
Why?
| | Catheter-Related Infections | 1 | 2012 | 98 | 0.340 |
Why?
| | Neoplasms | 2 | 2021 | 2944 | 0.330 |
Why?
| | Lung | 2 | 2022 | 4119 | 0.330 |
Why?
| | Bioterrorism | 3 | 2009 | 31 | 0.320 |
Why?
| | Infection Control | 1 | 2012 | 174 | 0.320 |
Why?
| | General Surgery | 3 | 2018 | 203 | 0.320 |
Why?
| | Genome, Insect | 2 | 2021 | 29 | 0.320 |
Why?
| | Education, Medical, Undergraduate | 3 | 2018 | 206 | 0.320 |
Why?
| | Comprehensive Health Care | 1 | 2010 | 24 | 0.320 |
Why?
| | Catheterization, Central Venous | 1 | 2012 | 120 | 0.320 |
Why?
| | National Health Programs | 2 | 2009 | 23 | 0.320 |
Why?
| | Public Policy | 1 | 2010 | 79 | 0.310 |
Why?
| | Endocytosis | 3 | 2022 | 168 | 0.310 |
Why?
| | Social Behavior | 3 | 2023 | 279 | 0.300 |
Why?
| | Bacteremia | 1 | 2012 | 218 | 0.300 |
Why?
| | Adult | 19 | 2026 | 40821 | 0.300 |
Why?
| | Health Plan Implementation | 1 | 2010 | 143 | 0.300 |
Why?
| | Curriculum | 5 | 2021 | 1074 | 0.290 |
Why?
| | Mitochondria, Heart | 2 | 2025 | 107 | 0.290 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1324 | 0.280 |
Why?
| | Fluorescent Dyes | 4 | 2019 | 340 | 0.280 |
Why?
| | Dental Implantation, Endosseous | 1 | 2008 | 3 | 0.280 |
Why?
| | Dental Prosthesis, Implant-Supported | 1 | 2008 | 7 | 0.270 |
Why?
| | Middle Aged | 14 | 2025 | 36359 | 0.270 |
Why?
| | Intraoperative Care | 2 | 2019 | 63 | 0.270 |
Why?
| | Hemorrhage | 2 | 2026 | 824 | 0.260 |
Why?
| | Career Choice | 3 | 2020 | 235 | 0.250 |
Why?
| | Viruses | 1 | 2009 | 165 | 0.250 |
Why?
| | Virus Diseases | 1 | 2009 | 219 | 0.250 |
Why?
| | BK Virus | 3 | 2013 | 18 | 0.250 |
Why?
| | Polyomavirus Infections | 3 | 2013 | 29 | 0.240 |
Why?
| | Tumor Virus Infections | 3 | 2013 | 51 | 0.240 |
Why?
| | Child Behavior | 2 | 2019 | 234 | 0.240 |
Why?
| | Glucose Tolerance Test | 2 | 2025 | 360 | 0.240 |
Why?
| | Myocytes, Cardiac | 2 | 2025 | 542 | 0.240 |
Why?
| | Sirtuin 2 | 1 | 2026 | 27 | 0.240 |
Why?
| | Nanocomposites | 1 | 2026 | 14 | 0.230 |
Why?
| | Alcohol Drinking in College | 1 | 2026 | 17 | 0.230 |
Why?
| | Aged | 9 | 2025 | 26251 | 0.230 |
Why?
| | Prospective Studies | 5 | 2023 | 8087 | 0.230 |
Why?
| | Endodontists | 1 | 2025 | 1 | 0.230 |
Why?
| | Endodontics | 1 | 2025 | 4 | 0.230 |
Why?
| | Technology, Dental | 1 | 2025 | 5 | 0.230 |
Why?
| | Infant, Newborn | 6 | 2024 | 6449 | 0.230 |
Why?
| | Herpesvirus 4, Human | 1 | 2026 | 172 | 0.220 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2025 | 2 | 0.220 |
Why?
| | Glutamate Carboxypeptidase II | 1 | 2025 | 8 | 0.220 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2026 | 102 | 0.220 |
Why?
| | Blood Glucose | 3 | 2025 | 2357 | 0.220 |
Why?
| | Uterus | 1 | 2026 | 227 | 0.210 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 6050 | 0.210 |
Why?
| | Pregnancy | 5 | 2025 | 7217 | 0.210 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2019 | 297 | 0.210 |
Why?
| | Antigens, Surface | 1 | 2025 | 155 | 0.210 |
Why?
| | Printing, Three-Dimensional | 1 | 2025 | 101 | 0.210 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2025 | 54 | 0.210 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2025 | 224 | 0.210 |
Why?
| | Autophagy | 4 | 2010 | 290 | 0.210 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2025 | 124 | 0.200 |
Why?
| | Apolipoprotein L1 | 1 | 2024 | 14 | 0.200 |
Why?
| | Motivational Interviewing | 1 | 2025 | 121 | 0.200 |
Why?
| | Spectroscopy, Near-Infrared | 3 | 2019 | 70 | 0.200 |
Why?
| | Virion | 2 | 2020 | 112 | 0.200 |
Why?
| | Cetuximab | 3 | 2019 | 110 | 0.200 |
Why?
| | Fibroblast Growth Factors | 1 | 2025 | 187 | 0.200 |
Why?
| | alpha-Synuclein | 1 | 2023 | 47 | 0.200 |
Why?
| | Haploidy | 1 | 2023 | 30 | 0.190 |
Why?
| | Variola virus | 1 | 2003 | 3 | 0.190 |
Why?
| | Transport Vesicles | 2 | 2018 | 22 | 0.190 |
Why?
| | Adenosine Triphosphatases | 3 | 2009 | 158 | 0.190 |
Why?
| | Diploidy | 1 | 2023 | 19 | 0.190 |
Why?
| | Smallpox | 1 | 2003 | 10 | 0.190 |
Why?
| | Herpesviridae | 1 | 2003 | 21 | 0.190 |
Why?
| | Health Care Surveys | 1 | 2025 | 538 | 0.190 |
Why?
| | Mass Screening | 2 | 2025 | 1300 | 0.190 |
Why?
| | Virus Replication | 3 | 2023 | 525 | 0.190 |
Why?
| | Vaping | 1 | 2024 | 81 | 0.190 |
Why?
| | Carrier Proteins | 2 | 2022 | 728 | 0.190 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3396 | 0.190 |
Why?
| | Parents | 2 | 2024 | 1393 | 0.190 |
Why?
| | Obstetrics | 1 | 2025 | 178 | 0.190 |
Why?
| | Guinea | 1 | 2022 | 3 | 0.190 |
Why?
| | Disaster Planning | 2 | 2006 | 109 | 0.180 |
Why?
| | Feeding Behavior | 2 | 2019 | 691 | 0.180 |
Why?
| | Internal-External Control | 1 | 2023 | 72 | 0.180 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2024 | 112 | 0.180 |
Why?
| | Ventricular Remodeling | 1 | 2025 | 283 | 0.180 |
Why?
| | Immunosenescence | 1 | 2022 | 5 | 0.180 |
Why?
| | Rats | 4 | 2026 | 5574 | 0.180 |
Why?
| | Cell Cycle Proteins | 4 | 2018 | 629 | 0.180 |
Why?
| | Mice | 20 | 2026 | 18266 | 0.180 |
Why?
| | Nucleocapsid | 1 | 2022 | 19 | 0.180 |
Why?
| | Self Report | 2 | 2026 | 869 | 0.180 |
Why?
| | Gene Frequency | 1 | 2023 | 495 | 0.180 |
Why?
| | Herpesviridae Infections | 1 | 2003 | 147 | 0.170 |
Why?
| | B-Lymphocytes | 2 | 2026 | 884 | 0.170 |
Why?
| | Retrospective Studies | 6 | 2023 | 17291 | 0.170 |
Why?
| | Hysterectomy | 1 | 2022 | 138 | 0.170 |
Why?
| | Biocompatible Materials | 1 | 2026 | 429 | 0.170 |
Why?
| | Clinical Competence | 3 | 2020 | 1261 | 0.170 |
Why?
| | Nephrotic Syndrome | 1 | 2022 | 44 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1754 | 0.170 |
Why?
| | Muscle Proteins | 3 | 2008 | 242 | 0.170 |
Why?
| | Natural History | 1 | 2021 | 3 | 0.170 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 481 | 0.170 |
Why?
| | Medication Adherence | 1 | 2025 | 535 | 0.170 |
Why?
| | Ethanol | 2 | 2023 | 629 | 0.170 |
Why?
| | Receptors, Odorant | 1 | 2021 | 32 | 0.170 |
Why?
| | Pediatric Obesity | 2 | 2019 | 635 | 0.170 |
Why?
| | Podocytes | 1 | 2022 | 80 | 0.170 |
Why?
| | Models, Biological | 5 | 2020 | 1758 | 0.160 |
Why?
| | Autopsy | 1 | 2021 | 96 | 0.160 |
Why?
| | Nanospheres | 1 | 2020 | 3 | 0.160 |
Why?
| | Thorax | 1 | 2020 | 51 | 0.160 |
Why?
| | Myositis, Inclusion Body | 3 | 2010 | 11 | 0.160 |
Why?
| | Cities | 1 | 2021 | 140 | 0.160 |
Why?
| | Cesarean Section | 1 | 2022 | 229 | 0.160 |
Why?
| | Epithelium | 2 | 2023 | 295 | 0.160 |
Why?
| | Rats, Sprague-Dawley | 1 | 2026 | 2533 | 0.160 |
Why?
| | Infant, Premature, Diseases | 1 | 2022 | 113 | 0.160 |
Why?
| | Biopsy | 3 | 2021 | 1073 | 0.160 |
Why?
| | Lip | 1 | 2020 | 23 | 0.160 |
Why?
| | Thrombocytopenia | 2 | 2020 | 205 | 0.160 |
Why?
| | Hallucinogens | 1 | 2022 | 112 | 0.160 |
Why?
| | Mutation Rate | 1 | 2020 | 37 | 0.160 |
Why?
| | Multivariate Analysis | 1 | 2024 | 1531 | 0.160 |
Why?
| | Students | 1 | 2026 | 647 | 0.160 |
Why?
| | Kidney Transplantation | 3 | 2013 | 702 | 0.160 |
Why?
| | Texas | 1 | 2021 | 279 | 0.160 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2020 | 4 | 0.150 |
Why?
| | Health Behavior | 2 | 2023 | 801 | 0.150 |
Why?
| | Breeding | 1 | 2020 | 64 | 0.150 |
Why?
| | Muscle, Skeletal | 5 | 2018 | 1795 | 0.150 |
Why?
| | Tendons | 1 | 2021 | 134 | 0.150 |
Why?
| | Interferon Regulatory Factors | 1 | 2020 | 45 | 0.150 |
Why?
| | Virus Assembly | 1 | 2020 | 81 | 0.150 |
Why?
| | Cell Surface Extensions | 1 | 2019 | 13 | 0.150 |
Why?
| | Pancreatic Neoplasms | 2 | 2019 | 944 | 0.150 |
Why?
| | Albumins | 1 | 2020 | 119 | 0.150 |
Why?
| | Seawater | 1 | 2019 | 33 | 0.150 |
Why?
| | Fresh Water | 1 | 2019 | 53 | 0.150 |
Why?
| | Maternal Health Services | 1 | 2021 | 99 | 0.150 |
Why?
| | Enteral Nutrition | 1 | 2022 | 212 | 0.150 |
Why?
| | Kidney Tubules, Proximal | 1 | 2020 | 127 | 0.150 |
Why?
| | Transfection | 3 | 2018 | 914 | 0.150 |
Why?
| | Kidney Diseases | 1 | 2024 | 427 | 0.150 |
Why?
| | Adult Stem Cells | 1 | 2019 | 39 | 0.150 |
Why?
| | Cleft Lip | 1 | 2020 | 73 | 0.150 |
Why?
| | Benchmarking | 1 | 2021 | 192 | 0.150 |
Why?
| | Cysts | 1 | 2020 | 108 | 0.150 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 175 | 0.150 |
Why?
| | Blood Transfusion | 1 | 2022 | 393 | 0.150 |
Why?
| | China | 1 | 2020 | 278 | 0.150 |
Why?
| | Educational Measurement | 2 | 2020 | 329 | 0.150 |
Why?
| | Fibrinogen | 1 | 2020 | 181 | 0.150 |
Why?
| | Geography | 1 | 2019 | 186 | 0.150 |
Why?
| | Zebrafish | 3 | 2022 | 533 | 0.140 |
Why?
| | Satiety Response | 1 | 2019 | 11 | 0.140 |
Why?
| | Specialties, Surgical | 1 | 2020 | 83 | 0.140 |
Why?
| | Cleft Palate | 1 | 2020 | 91 | 0.140 |
Why?
| | Species Specificity | 1 | 2020 | 542 | 0.140 |
Why?
| | Hyperphagia | 1 | 2019 | 37 | 0.140 |
Why?
| | Kingella kingae | 2 | 2009 | 12 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 200 | 0.140 |
Why?
| | Fimbriae, Bacterial | 2 | 2009 | 36 | 0.140 |
Why?
| | Staining and Labeling | 2 | 2012 | 148 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2020 | 193 | 0.140 |
Why?
| | Brain | 3 | 2021 | 2981 | 0.140 |
Why?
| | Exons | 2 | 2021 | 361 | 0.140 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 37 | 0.140 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2018 | 56 | 0.140 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2025 | 639 | 0.140 |
Why?
| | Harassment, Non-Sexual | 1 | 2018 | 1 | 0.140 |
Why?
| | Drug Approval | 1 | 2018 | 93 | 0.130 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 2097 | 0.130 |
Why?
| | Child | 7 | 2024 | 22638 | 0.130 |
Why?
| | Lipid Metabolism | 1 | 2022 | 533 | 0.130 |
Why?
| | Young Adult | 6 | 2026 | 14240 | 0.130 |
Why?
| | RNA, Viral | 2 | 2020 | 691 | 0.130 |
Why?
| | Family Relations | 1 | 2018 | 87 | 0.130 |
Why?
| | Violence | 1 | 2021 | 275 | 0.130 |
Why?
| | Age Factors | 1 | 2025 | 3321 | 0.130 |
Why?
| | Anti-HIV Agents | 1 | 2025 | 914 | 0.130 |
Why?
| | Endodeoxyribonucleases | 1 | 2018 | 77 | 0.130 |
Why?
| | Inclusion Bodies | 3 | 2023 | 27 | 0.130 |
Why?
| | Bacterial Adhesion | 2 | 2008 | 109 | 0.130 |
Why?
| | Predatory Behavior | 2 | 2015 | 53 | 0.130 |
Why?
| | Mitochondria | 2 | 2026 | 996 | 0.130 |
Why?
| | Nepal | 1 | 2017 | 31 | 0.130 |
Why?
| | Biomechanical Phenomena | 2 | 2018 | 868 | 0.130 |
Why?
| | Muscular Dystrophies, Limb-Girdle | 2 | 2008 | 6 | 0.130 |
Why?
| | Caveolae | 1 | 2017 | 15 | 0.130 |
Why?
| | Prostatic Neoplasms | 1 | 2025 | 972 | 0.130 |
Why?
| | Fishes | 2 | 2015 | 111 | 0.130 |
Why?
| | Notochord | 1 | 2017 | 14 | 0.130 |
Why?
| | Indoles | 2 | 2019 | 509 | 0.130 |
Why?
| | Memory, Short-Term | 1 | 2019 | 272 | 0.130 |
Why?
| | Hematopoiesis | 1 | 2018 | 195 | 0.130 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2021 | 437 | 0.130 |
Why?
| | Parkinson Disease | 1 | 2023 | 614 | 0.120 |
Why?
| | Mycobacterium marinum | 1 | 2016 | 4 | 0.120 |
Why?
| | Multimodal Imaging | 1 | 2018 | 138 | 0.120 |
Why?
| | Child, Preschool | 6 | 2024 | 11888 | 0.120 |
Why?
| | Family | 1 | 2021 | 680 | 0.120 |
Why?
| | Fractures, Bone | 1 | 2022 | 431 | 0.120 |
Why?
| | Gene Flow | 1 | 2017 | 91 | 0.120 |
Why?
| | Lipids | 1 | 2022 | 715 | 0.120 |
Why?
| | Observer Variation | 1 | 2017 | 355 | 0.120 |
Why?
| | Clinical Clerkship | 1 | 2018 | 108 | 0.120 |
Why?
| | Fluorescein Angiography | 1 | 2017 | 195 | 0.120 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2016 | 47 | 0.120 |
Why?
| | Alcoholism | 1 | 2023 | 830 | 0.120 |
Why?
| | Platelet-Derived Growth Factor | 2 | 2006 | 85 | 0.120 |
Why?
| | British Columbia | 1 | 2015 | 27 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2019 | 511 | 0.120 |
Why?
| | Pancreatectomy | 1 | 2019 | 289 | 0.110 |
Why?
| | Indians, North American | 2 | 2010 | 527 | 0.110 |
Why?
| | Cell Differentiation | 4 | 2021 | 1979 | 0.110 |
Why?
| | Adaptation, Physiological | 1 | 2019 | 567 | 0.110 |
Why?
| | Learning | 1 | 2020 | 446 | 0.110 |
Why?
| | Mutation | 8 | 2018 | 4082 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2018 | 274 | 0.110 |
Why?
| | Cannabis | 1 | 2022 | 519 | 0.110 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 1411 | 0.110 |
Why?
| | Accidental Falls | 1 | 2018 | 226 | 0.110 |
Why?
| | Intestinal Mucosa | 2 | 2019 | 666 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2022 | 1367 | 0.110 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2016 | 145 | 0.110 |
Why?
| | Simulation Training | 1 | 2017 | 136 | 0.110 |
Why?
| | Parenting | 1 | 2018 | 309 | 0.110 |
Why?
| | Mental Health | 1 | 2021 | 771 | 0.110 |
Why?
| | Poverty | 1 | 2019 | 530 | 0.110 |
Why?
| | Aged, 80 and over | 2 | 2025 | 8351 | 0.110 |
Why?
| | Urine | 2 | 2012 | 63 | 0.100 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 286 | 0.100 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2014 | 47 | 0.100 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2014 | 58 | 0.100 |
Why?
| | Insulin | 1 | 2025 | 2524 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2018 | 0.100 |
Why?
| | Motor Cortex | 1 | 2014 | 64 | 0.100 |
Why?
| | Kidney | 1 | 2021 | 1491 | 0.100 |
Why?
| | Adolescent Behavior | 1 | 2018 | 486 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 861 | 0.100 |
Why?
| | Endoribonucleases | 1 | 2014 | 80 | 0.100 |
Why?
| | Ubiquitin | 3 | 2009 | 84 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1992 | 0.100 |
Why?
| | Wound Healing | 3 | 2021 | 348 | 0.090 |
Why?
| | DNA Methylation | 1 | 2018 | 721 | 0.090 |
Why?
| | Methylene Blue | 1 | 2012 | 24 | 0.090 |
Why?
| | Fatty Acids | 1 | 2016 | 460 | 0.090 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2014 | 120 | 0.090 |
Why?
| | Antisepsis | 1 | 2012 | 1 | 0.090 |
Why?
| | Molecular Motor Proteins | 1 | 2012 | 28 | 0.090 |
Why?
| | Risk Factors | 4 | 2024 | 10840 | 0.090 |
Why?
| | Chlorhexidine | 1 | 2012 | 24 | 0.090 |
Why?
| | Heart | 1 | 2016 | 624 | 0.090 |
Why?
| | Pelvic Pain | 1 | 2012 | 43 | 0.090 |
Why?
| | Cell Line | 7 | 2018 | 2809 | 0.090 |
Why?
| | Endometriosis | 1 | 2012 | 58 | 0.090 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2014 | 139 | 0.090 |
Why?
| | Neural Stem Cells | 1 | 2014 | 167 | 0.090 |
Why?
| | Internship and Residency | 2 | 2020 | 1269 | 0.090 |
Why?
| | Equipment Contamination | 1 | 2012 | 67 | 0.090 |
Why?
| | Myelin Sheath | 1 | 2014 | 166 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2228 | 0.090 |
Why?
| | Mutation, Missense | 2 | 2010 | 331 | 0.090 |
Why?
| | Recovery of Function | 1 | 2016 | 721 | 0.090 |
Why?
| | Oligodendroglia | 1 | 2014 | 198 | 0.090 |
Why?
| | Myosin Heavy Chains | 1 | 2012 | 177 | 0.080 |
Why?
| | Sleep | 1 | 2019 | 896 | 0.080 |
Why?
| | Tissue Engineering | 2 | 2025 | 439 | 0.080 |
Why?
| | Receptors, Progesterone | 1 | 2013 | 241 | 0.080 |
Why?
| | Peptides | 4 | 2013 | 991 | 0.080 |
Why?
| | Infant | 3 | 2022 | 10093 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2018 | 700 | 0.080 |
Why?
| | Program Evaluation | 2 | 2017 | 945 | 0.080 |
Why?
| | Guam | 1 | 2010 | 17 | 0.080 |
Why?
| | Oklahoma | 1 | 2010 | 21 | 0.080 |
Why?
| | Myocardium | 1 | 2016 | 948 | 0.080 |
Why?
| | DNA, Viral | 1 | 2012 | 352 | 0.080 |
Why?
| | Mice, Transgenic | 5 | 2024 | 2131 | 0.080 |
Why?
| | Multienzyme Complexes | 1 | 2010 | 65 | 0.080 |
Why?
| | Microscopy, Immunoelectron | 2 | 2022 | 38 | 0.080 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2013 | 257 | 0.080 |
Why?
| | Cell Line, Tumor | 5 | 2025 | 3538 | 0.080 |
Why?
| | Muscle Weakness | 2 | 2010 | 92 | 0.080 |
Why?
| | Fish Diseases | 1 | 2010 | 18 | 0.080 |
Why?
| | Fluorescent Antibody Technique | 2 | 2022 | 345 | 0.080 |
Why?
| | Osteitis Deformans | 1 | 2009 | 9 | 0.080 |
Why?
| | Knowledge | 2 | 2021 | 62 | 0.080 |
Why?
| | Arthrogryposis | 1 | 2010 | 17 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2012 | 234 | 0.070 |
Why?
| | Health Care Reform | 1 | 2010 | 109 | 0.070 |
Why?
| | Immunohistochemistry | 3 | 2022 | 1709 | 0.070 |
Why?
| | RNA Polymerase Sigma 54 | 1 | 2009 | 3 | 0.070 |
Why?
| | Adolescent | 6 | 2026 | 22451 | 0.070 |
Why?
| | Computer Simulation | 2 | 2018 | 1014 | 0.070 |
Why?
| | Fimbriae Proteins | 1 | 2009 | 25 | 0.070 |
Why?
| | Case-Control Studies | 4 | 2022 | 3633 | 0.070 |
Why?
| | Frontotemporal Dementia | 1 | 2009 | 56 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2022 | 2411 | 0.070 |
Why?
| | Luciferases | 1 | 2009 | 153 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4565 | 0.070 |
Why?
| | Norwalk virus | 1 | 2008 | 1 | 0.070 |
Why?
| | Quadriceps Muscle | 1 | 2009 | 120 | 0.070 |
Why?
| | Biological Assay | 1 | 2009 | 133 | 0.070 |
Why?
| | History, 21st Century | 1 | 2009 | 224 | 0.070 |
Why?
| | Dental Abutments | 1 | 2008 | 1 | 0.070 |
Why?
| | Denture, Partial, Immediate | 1 | 2008 | 2 | 0.070 |
Why?
| | Dental Prosthesis Design | 1 | 2008 | 2 | 0.070 |
Why?
| | Dental Restoration Failure | 1 | 2008 | 6 | 0.070 |
Why?
| | Gene Expression Regulation, Viral | 2 | 2014 | 92 | 0.070 |
Why?
| | Macrophages | 1 | 2016 | 1530 | 0.070 |
Why?
| | Genes, Reporter | 1 | 2009 | 273 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 41 | 0.070 |
Why?
| | Haemophilus | 1 | 2008 | 8 | 0.070 |
Why?
| | Maxilla | 1 | 2008 | 36 | 0.070 |
Why?
| | Cyclic GMP-Dependent Protein Kinases | 1 | 2008 | 4 | 0.070 |
Why?
| | Fas Ligand Protein | 1 | 2008 | 61 | 0.070 |
Why?
| | Incisor | 1 | 2008 | 22 | 0.070 |
Why?
| | History, 20th Century | 1 | 2009 | 330 | 0.070 |
Why?
| | Computer-Aided Design | 1 | 2008 | 39 | 0.070 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 54 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 6021 | 0.070 |
Why?
| | Adhesins, Bacterial | 1 | 2008 | 44 | 0.070 |
Why?
| | Transcriptome | 1 | 2014 | 1066 | 0.070 |
Why?
| | Microscopy, Fluorescence | 2 | 2019 | 403 | 0.070 |
Why?
| | Gastroenteritis | 1 | 2008 | 63 | 0.070 |
Why?
| | Models, Anatomic | 1 | 2008 | 87 | 0.060 |
Why?
| | Cell Membrane | 2 | 2016 | 701 | 0.060 |
Why?
| | Health Policy | 1 | 2010 | 399 | 0.060 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2008 | 125 | 0.060 |
Why?
| | Molecular Sequence Data | 5 | 2010 | 2835 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2013 | 927 | 0.060 |
Why?
| | Population Surveillance | 1 | 2009 | 477 | 0.060 |
Why?
| | Myofibrils | 1 | 2006 | 55 | 0.060 |
Why?
| | Sentinel Surveillance | 1 | 2006 | 48 | 0.060 |
Why?
| | Bone Regeneration | 1 | 2006 | 28 | 0.060 |
Why?
| | Communicable Diseases, Emerging | 1 | 2006 | 39 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2008 | 319 | 0.060 |
Why?
| | Periodontitis | 1 | 2006 | 55 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2025 | 4112 | 0.060 |
Why?
| | Cytoskeletal Proteins | 1 | 2006 | 146 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2008 | 384 | 0.060 |
Why?
| | Antilymphocyte Serum | 2 | 2021 | 55 | 0.060 |
Why?
| | Acetylation | 1 | 2026 | 262 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5875 | 0.060 |
Why?
| | Follow-Up Studies | 4 | 2020 | 5397 | 0.060 |
Why?
| | Rabbits | 2 | 2022 | 647 | 0.060 |
Why?
| | Bacterial Proteins | 2 | 2009 | 976 | 0.060 |
Why?
| | Periodontal Diseases | 1 | 2006 | 62 | 0.060 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2008 | 449 | 0.050 |
Why?
| | Laboratories | 1 | 2006 | 109 | 0.050 |
Why?
| | Gelatin | 1 | 2025 | 56 | 0.050 |
Why?
| | Binge Drinking | 1 | 2025 | 44 | 0.050 |
Why?
| | Ecological Momentary Assessment | 1 | 2025 | 49 | 0.050 |
Why?
| | Bioprinting | 1 | 2025 | 34 | 0.050 |
Why?
| | Methacrylates | 1 | 2025 | 119 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2026 | 149 | 0.050 |
Why?
| | Neurons | 1 | 2014 | 1663 | 0.050 |
Why?
| | Enterotoxins | 1 | 2004 | 89 | 0.050 |
Why?
| | Valosin Containing Protein | 3 | 2009 | 8 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2021 | 3930 | 0.050 |
Why?
| | Interleukin-15 | 1 | 2025 | 96 | 0.050 |
Why?
| | Smoke-Free Policy | 1 | 2024 | 13 | 0.050 |
Why?
| | Nephritis | 1 | 2004 | 22 | 0.050 |
Why?
| | Opportunistic Infections | 1 | 2004 | 47 | 0.050 |
Why?
| | Bacterial Toxins | 1 | 2004 | 109 | 0.050 |
Why?
| | Acridine Orange | 1 | 2004 | 4 | 0.050 |
Why?
| | Intestine, Large | 1 | 2004 | 13 | 0.050 |
Why?
| | Blood Coagulation | 1 | 2026 | 267 | 0.050 |
Why?
| | Nucleocapsid Proteins | 1 | 2023 | 28 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2026 | 2497 | 0.050 |
Why?
| | Disease Outbreaks | 2 | 2022 | 420 | 0.050 |
Why?
| | Risk Assessment | 2 | 2010 | 3678 | 0.050 |
Why?
| | Universities | 1 | 2026 | 450 | 0.050 |
Why?
| | Plasmids | 2 | 2018 | 372 | 0.050 |
Why?
| | Virulence Factors | 1 | 2004 | 175 | 0.050 |
Why?
| | Endothelial Cells | 2 | 2020 | 876 | 0.050 |
Why?
| | Inclusion Bodies, Viral | 1 | 2002 | 3 | 0.050 |
Why?
| | Dopaminergic Neurons | 1 | 2023 | 67 | 0.050 |
Why?
| | Viral Structural Proteins | 1 | 2002 | 12 | 0.050 |
Why?
| | Glycolysis | 1 | 2025 | 341 | 0.050 |
Why?
| | Orthopoxvirus | 1 | 2002 | 4 | 0.050 |
Why?
| | Immunoblotting | 2 | 2016 | 294 | 0.050 |
Why?
| | Escherichia coli Proteins | 1 | 2004 | 200 | 0.050 |
Why?
| | Light | 1 | 2025 | 400 | 0.050 |
Why?
| | Gene Deletion | 2 | 2018 | 384 | 0.050 |
Why?
| | Adenine | 1 | 2025 | 338 | 0.050 |
Why?
| | Rejuvenation | 1 | 2022 | 18 | 0.040 |
Why?
| | Vero Cells | 1 | 2022 | 84 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2008 | 1118 | 0.040 |
Why?
| | HIV-1 | 1 | 2008 | 911 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 74 | 0.040 |
Why?
| | Fracture Healing | 1 | 2022 | 91 | 0.040 |
Why?
| | Thymocytes | 1 | 2021 | 33 | 0.040 |
Why?
| | Ki-67 Antigen | 1 | 2022 | 119 | 0.040 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2021 | 26 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 928 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2022 | 122 | 0.040 |
Why?
| | Trastuzumab | 1 | 2022 | 119 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2024 | 746 | 0.040 |
Why?
| | Intubation, Gastrointestinal | 1 | 2022 | 76 | 0.040 |
Why?
| | Biofilms | 1 | 2004 | 288 | 0.040 |
Why?
| | Impulsive Behavior | 1 | 2022 | 146 | 0.040 |
Why?
| | Fasting | 1 | 2022 | 280 | 0.040 |
Why?
| | Transcription Factors | 1 | 2009 | 1728 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2025 | 1136 | 0.040 |
Why?
| | United Kingdom | 1 | 2022 | 376 | 0.040 |
Why?
| | Graft Rejection | 1 | 2004 | 504 | 0.040 |
Why?
| | Belgium | 1 | 2020 | 10 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 129 | 0.040 |
Why?
| | Recombination, Genetic | 2 | 2017 | 202 | 0.040 |
Why?
| | Cooperative Behavior | 1 | 2023 | 467 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 11744 | 0.040 |
Why?
| | Quinazolines | 1 | 2022 | 267 | 0.040 |
Why?
| | Tendon Injuries | 1 | 2021 | 73 | 0.040 |
Why?
| | Colorado | 1 | 2010 | 4588 | 0.040 |
Why?
| | Escherichia coli | 1 | 2004 | 831 | 0.040 |
Why?
| | CRISPR-Cas Systems | 1 | 2022 | 163 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 745 | 0.040 |
Why?
| | Chloroquine | 2 | 2010 | 54 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2022 | 376 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 413 | 0.040 |
Why?
| | Aggression | 1 | 2021 | 170 | 0.040 |
Why?
| | Platelet Aggregation | 1 | 2020 | 99 | 0.040 |
Why?
| | Endothelium | 1 | 2020 | 119 | 0.040 |
Why?
| | Myofibroblasts | 1 | 2021 | 149 | 0.040 |
Why?
| | Patient Care | 1 | 2021 | 120 | 0.040 |
Why?
| | RNA Interference | 2 | 2013 | 470 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1878 | 0.040 |
Why?
| | Education | 1 | 2020 | 102 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 2 | 2010 | 184 | 0.040 |
Why?
| | Contraception | 1 | 2021 | 170 | 0.040 |
Why?
| | Tissue Embedding | 1 | 2018 | 3 | 0.040 |
Why?
| | Pinocytosis | 1 | 2018 | 6 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 610 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 474 | 0.040 |
Why?
| | Mutation Accumulation | 1 | 2018 | 2 | 0.040 |
Why?
| | Clathrin | 1 | 2018 | 26 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2025 | 930 | 0.040 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 371 | 0.040 |
Why?
| | Electricity | 1 | 2018 | 26 | 0.030 |
Why?
| | Digoxin | 1 | 2018 | 27 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 483 | 0.030 |
Why?
| | Cultural Characteristics | 1 | 2018 | 65 | 0.030 |
Why?
| | Hunger | 1 | 2019 | 56 | 0.030 |
Why?
| | Zebrafish Proteins | 1 | 2022 | 314 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 538 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2018 | 81 | 0.030 |
Why?
| | Viral Load | 2 | 2012 | 525 | 0.030 |
Why?
| | Veins | 1 | 2018 | 68 | 0.030 |
Why?
| | Germ Cells | 1 | 2018 | 66 | 0.030 |
Why?
| | Drosophila | 1 | 2019 | 168 | 0.030 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2018 | 102 | 0.030 |
Why?
| | Postpartum Period | 1 | 2021 | 377 | 0.030 |
Why?
| | Physician Assistants | 1 | 2020 | 101 | 0.030 |
Why?
| | Decision Making | 1 | 2025 | 987 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2019 | 173 | 0.030 |
Why?
| | Microtubules | 1 | 2019 | 223 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2019 | 335 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2025 | 3121 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2008 | 2766 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2012 | 1030 | 0.030 |
Why?
| | Computer-Assisted Instruction | 1 | 2018 | 69 | 0.030 |
Why?
| | Biological Transport | 1 | 2018 | 423 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1051 | 0.030 |
Why?
| | Self Efficacy | 1 | 2021 | 417 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 2018 | 184 | 0.030 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2009 | 214 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1372 | 0.030 |
Why?
| | Binding Sites | 1 | 2020 | 1306 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2025 | 1212 | 0.030 |
Why?
| | Prognosis | 2 | 2018 | 4331 | 0.030 |
Why?
| | Sarcolemma | 2 | 2007 | 33 | 0.030 |
Why?
| | Schools, Medical | 1 | 2018 | 157 | 0.030 |
Why?
| | Isolated Heart Preparation | 1 | 2016 | 6 | 0.030 |
Why?
| | Signal Transduction | 2 | 2025 | 5234 | 0.030 |
Why?
| | Faculty | 1 | 2018 | 151 | 0.030 |
Why?
| | Mutant Proteins | 2 | 2007 | 103 | 0.030 |
Why?
| | Microfilament Proteins | 2 | 2008 | 135 | 0.030 |
Why?
| | Organizational Culture | 1 | 2018 | 159 | 0.030 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2016 | 112 | 0.030 |
Why?
| | Gene Expression Regulation, Bacterial | 2 | 2009 | 337 | 0.030 |
Why?
| | Neutrophils | 1 | 2022 | 1132 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 973 | 0.030 |
Why?
| | Quality Improvement | 1 | 2025 | 1325 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 2 | 2006 | 38 | 0.030 |
Why?
| | Granuloma | 1 | 2016 | 96 | 0.030 |
Why?
| | Cues | 1 | 2018 | 326 | 0.030 |
Why?
| | Eating | 1 | 2019 | 386 | 0.030 |
Why?
| | Nutritional Status | 1 | 2018 | 344 | 0.030 |
Why?
| | Patient Safety | 1 | 2020 | 351 | 0.030 |
Why?
| | Energy Intake | 1 | 2019 | 506 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2021 | 704 | 0.030 |
Why?
| | California | 1 | 2017 | 473 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2019 | 636 | 0.030 |
Why?
| | Necrosis | 1 | 2016 | 243 | 0.030 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2016 | 140 | 0.030 |
Why?
| | Collagen Type I | 2 | 2006 | 144 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1156 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2017 | 493 | 0.030 |
Why?
| | Amino Acid Transport Systems, Basic | 1 | 2014 | 4 | 0.030 |
Why?
| | Cadherins | 1 | 2016 | 201 | 0.030 |
Why?
| | Placenta | 1 | 2021 | 794 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2016 | 292 | 0.030 |
Why?
| | Focus Groups | 1 | 2018 | 587 | 0.030 |
Why?
| | Thy-1 Antigens | 1 | 2014 | 11 | 0.030 |
Why?
| | Channelrhodopsins | 1 | 2014 | 19 | 0.030 |
Why?
| | Mentoring | 1 | 2017 | 165 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 1125 | 0.030 |
Why?
| | Activating Transcription Factor 6 | 1 | 2014 | 19 | 0.030 |
Why?
| | Alleles | 1 | 2017 | 900 | 0.030 |
Why?
| | HeLa Cells | 2 | 2008 | 635 | 0.030 |
Why?
| | Primates | 1 | 2014 | 133 | 0.030 |
Why?
| | Corpus Callosum | 1 | 2014 | 76 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2014 | 290 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2018 | 926 | 0.020 |
Why?
| | Emotions | 1 | 2019 | 555 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1062 | 0.020 |
Why?
| | Apoptosis | 1 | 2022 | 2436 | 0.020 |
Why?
| | Base Pairing | 1 | 2013 | 65 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2013 | 197 | 0.020 |
Why?
| | Cell Survival | 1 | 2016 | 1102 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2013 | 74 | 0.020 |
Why?
| | Mitochondrial Membranes | 1 | 2013 | 40 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 2012 | 30 | 0.020 |
Why?
| | Mycobacterium tuberculosis | 1 | 2016 | 325 | 0.020 |
Why?
| | Cell Respiration | 1 | 2013 | 104 | 0.020 |
Why?
| | Nephritis, Hereditary | 1 | 2012 | 3 | 0.020 |
Why?
| | Recombinant Proteins | 2 | 2006 | 1361 | 0.020 |
Why?
| | Progestins | 1 | 2013 | 67 | 0.020 |
Why?
| | Cerebral Infarction | 1 | 2012 | 46 | 0.020 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2012 | 193 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2591 | 0.020 |
Why?
| | RNA Splicing | 1 | 2014 | 287 | 0.020 |
Why?
| | Cell Lineage | 1 | 2014 | 375 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1996 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2016 | 586 | 0.020 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2012 | 66 | 0.020 |
Why?
| | DNA | 1 | 2018 | 1418 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2014 | 268 | 0.020 |
Why?
| | Protein Transport | 1 | 2013 | 439 | 0.020 |
Why?
| | Muscle Denervation | 1 | 2010 | 8 | 0.020 |
Why?
| | Colchicine | 1 | 2010 | 20 | 0.020 |
Why?
| | Tubulin Modulators | 1 | 2010 | 10 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2013 | 263 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2014 | 501 | 0.020 |
Why?
| | Vinblastine | 1 | 2010 | 75 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2014 | 366 | 0.020 |
Why?
| | Hemorrhagic Septicemia, Viral | 1 | 2010 | 1 | 0.020 |
Why?
| | Mesomycetozoea | 1 | 2010 | 1 | 0.020 |
Why?
| | Mesomycetozoea Infections | 1 | 2010 | 1 | 0.020 |
Why?
| | Pacific Ocean | 1 | 2010 | 8 | 0.020 |
Why?
| | Ulcer | 1 | 2010 | 37 | 0.020 |
Why?
| | Calcium | 1 | 2016 | 1181 | 0.020 |
Why?
| | Sequestosome-1 Protein | 1 | 2009 | 15 | 0.020 |
Why?
| | Genes, Dominant | 1 | 2010 | 94 | 0.020 |
Why?
| | Qualitative Research | 1 | 2018 | 1720 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1403 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4329 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2013 | 728 | 0.020 |
Why?
| | Tissue Extracts | 1 | 2009 | 19 | 0.020 |
Why?
| | Population Dynamics | 1 | 2010 | 142 | 0.020 |
Why?
| | Motor Activity | 1 | 2014 | 701 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 395 | 0.020 |
Why?
| | Protein Structure, Quaternary | 1 | 2009 | 106 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2010 | 388 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2009 | 140 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2009 | 88 | 0.020 |
Why?
| | Synovial Fluid | 1 | 2008 | 69 | 0.020 |
Why?
| | Caliciviridae Infections | 1 | 2008 | 18 | 0.020 |
Why?
| | Isoleucine | 1 | 2008 | 15 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2008 | 82 | 0.020 |
Why?
| | Threonine | 1 | 2008 | 43 | 0.020 |
Why?
| | Fibroblasts | 1 | 2014 | 1033 | 0.020 |
Why?
| | Laparoscopy | 1 | 2012 | 474 | 0.020 |
Why?
| | Monte Carlo Method | 1 | 2008 | 150 | 0.020 |
Why?
| | Dimerization | 1 | 2008 | 174 | 0.020 |
Why?
| | Antirheumatic Agents | 1 | 2010 | 309 | 0.020 |
Why?
| | Oxygen | 1 | 2013 | 996 | 0.020 |
Why?
| | Myosins | 1 | 2008 | 131 | 0.020 |
Why?
| | Sirolimus | 1 | 2009 | 282 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 6045 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 330 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2009 | 662 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2010 | 449 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2009 | 427 | 0.020 |
Why?
| | Cell Death | 1 | 2008 | 379 | 0.020 |
Why?
| | Chronic Disease | 1 | 2012 | 1824 | 0.020 |
Why?
| | Connectin | 1 | 2006 | 43 | 0.010 |
Why?
| | Organ Specificity | 1 | 2007 | 306 | 0.010 |
Why?
| | Guided Tissue Regeneration, Periodontal | 1 | 2006 | 1 | 0.010 |
Why?
| | Base Sequence | 1 | 2010 | 2119 | 0.010 |
Why?
| | Alveolar Bone Loss | 1 | 2006 | 9 | 0.010 |
Why?
| | Calcium Phosphates | 1 | 2006 | 28 | 0.010 |
Why?
| | Bone Substitutes | 1 | 2006 | 26 | 0.010 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 155 | 0.010 |
Why?
| | Genetic Engineering | 1 | 2006 | 87 | 0.010 |
Why?
| | Physical Conditioning, Animal | 1 | 2008 | 242 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2006 | 334 | 0.010 |
Why?
| | Models, Genetic | 1 | 2008 | 537 | 0.010 |
Why?
| | Muscles | 1 | 2006 | 330 | 0.010 |
Why?
| | Caveolins | 1 | 2004 | 4 | 0.010 |
Why?
| | Periplasm | 1 | 2004 | 13 | 0.010 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2004 | 45 | 0.010 |
Why?
| | HT29 Cells | 1 | 2004 | 37 | 0.010 |
Why?
| | Caveolin 1 | 1 | 2004 | 20 | 0.010 |
Why?
| | Membrane Microdomains | 1 | 2004 | 32 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2013 | 2783 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2009 | 1236 | 0.010 |
Why?
| | Specimen Handling | 1 | 2006 | 178 | 0.010 |
Why?
| | Methylprednisolone | 1 | 2004 | 58 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2008 | 683 | 0.010 |
Why?
| | Regeneration | 1 | 2006 | 198 | 0.010 |
Why?
| | Papio | 1 | 2004 | 70 | 0.010 |
Why?
| | Virulence | 1 | 2004 | 287 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2006 | 543 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1717 | 0.010 |
Why?
| | Muscle Contraction | 1 | 2006 | 427 | 0.010 |
Why?
| | Cowpox virus | 1 | 2002 | 2 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 2002 | 72 | 0.010 |
Why?
| | Vaccinia virus | 1 | 2002 | 35 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2009 | 1429 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2006 | 377 | 0.010 |
Why?
| | Immunoglobulin A | 1 | 2004 | 205 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2009 | 1467 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2006 | 693 | 0.010 |
Why?
| | Protein Binding | 1 | 2008 | 2239 | 0.010 |
Why?
| | Gene Expression | 1 | 2007 | 1461 | 0.010 |
Why?
| | Public Health | 1 | 2006 | 573 | 0.010 |
Why?
| | Glucocorticoids | 1 | 2004 | 536 | 0.010 |
Why?
| | Viral Proteins | 1 | 2002 | 350 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 824 | 0.010 |
Why?
| | Communication | 1 | 2006 | 979 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2088 | 0.010 |
Why?
| | Disease Progression | 1 | 2006 | 2857 | 0.010 |
Why?
| | Algorithms | 1 | 2006 | 1843 | 0.010 |
Why?
| | Bacteria | 1 | 2004 | 766 | 0.010 |
Why?
| | Incidence | 1 | 2004 | 2910 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 7079 | 0.010 |
Why?
|
|
Miller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|